Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Banking on the placenta

How Celularity’s placenta-derived cells could make naturally allogeneic products

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into the clinic. The newco disclosed today it has amassed more than $250 million in funding and assets, a rich IP portfolio and a list of banner names in its leadership team.

Celgene is joined by Sorrento Therapeutics Inc., United Therapeutics Corp., Human Longevity Inc. and undisclosed private investors, who announced an undisclosed series A round in August. The four companies own about a 50% stake in the company between them, and are providing access to core technologies to support Celularity’s platform.

Celularity’s assets include tissue regeneration products, four clinical cell therapies, one cell therapy nearing IND submission, and a preclinical platform for developing products centered on placental cells for treating cancer.

“Pretty much any disorders associated with failure of the immune system or regenerative processes were potential targets for the company,” said Robert Hariri, Celuarity co-founder, chairman and CEO.

The technology has been advanced within Celgene by Hariri for 15 years, since the acquisition of Hariri’s previous company Anthrogenesis Corp.,

Read the full 1940 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers